Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : opens access to pathology imaging tools to improve patient care

09/15/2021 | 01:01am EDT
  • Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analysis tools
  • Artificial intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment
  • Open digital pathology environments can break down barriers to allow for rapid technology advances across industry and research partners, which is critical in developing next-generation diagnostic tests

Basel, 15 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the introduction of the Roche Digital Pathology Open Environment that allows software developers to easily integrate their image analysis tools for tumour tissue with Roche’s uPath enterprise software, an application for pathologist workflow. This open environment allows for the secure exchange and flow of data so that pathologists can access advanced algorithms from third parties alongside Roche’s menu of artificial intelligence-based image analysis tools. This enables software developers globally to distribute their digital products through Roche’s uPath software, offering a broader set of diagnostic tools for pathologists and ultimately the potential for better and faster answers for patients.

As artificial intelligence tools proposed for clinical use continue to develop, industry and research partners may leverage Roche’s Open Environment. This access expands the ability for pathologists to more easily read images generated from the VENTANA DP 200 slide scanner, which is needed for image analysis algorithm development. This also allows for partnerships between researchers and developers, which can result in greater access to innovative imaging tools for laboratories and healthcare providers for both research and clinical use.

“Roche is at the center of digital transformation for pathology, and is investing heavily in this innovation to improve patient outcomes,” said Thomas Schinecker, CEO Roche Diagnostics. “Providing pathologists with access to innovative digital tools from Roche and our collaborators through an open environment is critical for laboratory customers and the patients they serve.”

About Roche Digital Pathology
As the leading provider of pathology lab solutions, Roche is delivering the end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms. We minimise variables that can impact analysis, and it is this end-to-end development that produces the quality results healthcare providers and researchers can depend on. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented tools into routine clinical practice and is committed to investing in and shaping the future of pathology. Find more information.

The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO). Image analysis algorithms developed by third-party entities and their utilisation are the responsibility of the third party provider.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Patrick Barth
Phone: +41 61 688 44 86

 
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31

 
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05


Roche Investor Relations  
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com

 
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

 
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
   
Investor Relations North America  
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
 

 

Attachment

  • 15092021_MR_Digital Pathology Open Environment_en

© OMX, source GlobeNewswire - EU Press Releases

All news about ROCHE HOLDING AG
10/15ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E..
BU
10/15ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea..
AQ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq -2-
DJ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people..
DJ
10/15GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
DJ
10/15ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists
MT
10/15ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology..
AQ
10/15PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig..
DJ
10/14ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month
RE
10/14ROCHE : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatmen..
PU
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 787 M 66 909 M 66 909 M
Net income 2021 14 572 M 15 780 M 15 780 M
Net cash 2021 4 469 M 4 840 M 4 840 M
P/E ratio 2021 20,9x
Yield 2021 2,60%
Capitalization 313 B 339 B 339 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,86x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 360,25 CHF
Average target price 382,53 CHF
Spread / Average Target 6,19%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.59%339 442
JOHNSON & JOHNSON2.49%424 619
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283